LT3960B - Process for preparing hypoglycemic compounds - Google Patents
Process for preparing hypoglycemic compounds Download PDFInfo
- Publication number
- LT3960B LT3960B LTIP1647A LTIP1647A LT3960B LT 3960 B LT3960 B LT 3960B LT IP1647 A LTIP1647 A LT IP1647A LT IP1647 A LTIP1647 A LT IP1647A LT 3960 B LT3960 B LT 3960B
- Authority
- LT
- Lithuania
- Prior art keywords
- morpholinophenyl
- hours
- formula
- compounds
- mixture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 42
- 230000002218 hypoglycaemic effect Effects 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 20
- -1 methylpiperazinyl Chemical group 0.000 claims description 18
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 4
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract description 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QKWLVAYDAHQMLG-UHFFFAOYSA-N 2-morpholin-4-ylaniline Chemical compound NC1=CC=CC=C1N1CCOCC1 QKWLVAYDAHQMLG-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HNAAKIPAJBGKCC-UHFFFAOYSA-N 2-morpholin-4-ylaniline;hydrochloride Chemical compound Cl.NC1=CC=CC=C1N1CCOCC1 HNAAKIPAJBGKCC-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 4
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- YIMGGHGOVMBIJO-UHFFFAOYSA-N 1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=CC=CC=C1N1CCOCC1 YIMGGHGOVMBIJO-UHFFFAOYSA-N 0.000 description 3
- WECUSHSUUIHVCH-UHFFFAOYSA-N 2-methyl-n'-(2-morpholin-4-ylphenyl)propanimidamide Chemical compound CC(C)C(=N)NC1=CC=CC=C1N1CCOCC1 WECUSHSUUIHVCH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 3
- OAGOUCJGXNLJNL-UHFFFAOYSA-N dimethylcyanamide Chemical compound CN(C)C#N OAGOUCJGXNLJNL-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- SLSVHNSMVHATQA-UHFFFAOYSA-N 2,2-dimethyl-n'-(2-morpholin-4-ylphenyl)propanimidamide Chemical compound CC(C)(C)C(=N)NC1=CC=CC=C1N1CCOCC1 SLSVHNSMVHATQA-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- RFFFKMOABOFIDF-UHFFFAOYSA-N Pentanenitrile Chemical compound CCCCC#N RFFFKMOABOFIDF-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- FTIAGMOESLWRPG-UHFFFAOYSA-N methyl 3-[[amino(dimethylamino)methylidene]amino]-4-morpholin-4-ylbenzoate Chemical compound CN(C)C(N)=NC1=CC(C(=O)OC)=CC=C1N1CCOCC1 FTIAGMOESLWRPG-UHFFFAOYSA-N 0.000 description 2
- PTGWNQXYFRYROU-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)ethanimidamide Chemical compound CC(=N)NC1=CC=CC=C1N1CCOCC1 PTGWNQXYFRYROU-UHFFFAOYSA-N 0.000 description 2
- SPVWQWQRTCPMHZ-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)pentanimidamide Chemical compound CCCCC(=N)NC1=CC=CC=C1N1CCOCC1 SPVWQWQRTCPMHZ-UHFFFAOYSA-N 0.000 description 2
- BENIFPFKIDBRNI-UHFFFAOYSA-N n'-(5-fluoro-2-morpholin-4-ylphenyl)-2-methylpropanimidamide Chemical compound CC(C)C(=N)NC1=CC(F)=CC=C1N1CCOCC1 BENIFPFKIDBRNI-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZYPZFGGOCOBOJP-WLHGVMLRSA-N (E)-but-2-enedioic acid N'-(2-morpholin-4-ylphenyl)butanimidamide Chemical compound OC(=O)\C=C\C(O)=O.CCCC(=N)NC1=CC=CC=C1N1CCOCC1 ZYPZFGGOCOBOJP-WLHGVMLRSA-N 0.000 description 1
- KHABPRMUUQCJLV-TYYBGVCCSA-N (e)-but-2-enedioic acid;guanidine Chemical compound NC(N)=N.OC(=O)\C=C\C(O)=O KHABPRMUUQCJLV-TYYBGVCCSA-N 0.000 description 1
- WVLQNRALFCAULM-UHFFFAOYSA-N 1,1-dimethyl-2-(2-methyl-6-morpholin-4-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=C(C)C=CC=C1N1CCOCC1 WVLQNRALFCAULM-UHFFFAOYSA-N 0.000 description 1
- OHFMKFHVEXXQGP-UHFFFAOYSA-N 1,1-dimethyl-2-(2-piperidin-1-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=CC=CC=C1N1CCCCC1 OHFMKFHVEXXQGP-UHFFFAOYSA-N 0.000 description 1
- OSKSHTLFBRFGHZ-UHFFFAOYSA-N 1,1-dimethyl-2-(4-methyl-2-morpholin-4-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=CC=C(C)C=C1N1CCOCC1 OSKSHTLFBRFGHZ-UHFFFAOYSA-N 0.000 description 1
- CMFUNUPPYXTXKB-UHFFFAOYSA-N 1,1-dimethyl-2-(5-methyl-2-morpholin-4-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=CC(C)=CC=C1N1CCOCC1 CMFUNUPPYXTXKB-UHFFFAOYSA-N 0.000 description 1
- ZFMPDYCKJRMUTD-UHFFFAOYSA-N 1,1-dimethyl-2-(5-methylsulfanyl-2-morpholin-4-ylphenyl)guanidine Chemical compound CN(C)C(N)=NC1=CC(SC)=CC=C1N1CCOCC1 ZFMPDYCKJRMUTD-UHFFFAOYSA-N 0.000 description 1
- DLFWLHAFKJXQFP-UHFFFAOYSA-N 1,1-dimethyl-2-[2-(1,2,4-oxathiazinan-4-yl)phenyl]guanidine Chemical compound CN(C)C(N)=NC1=CC=CC=C1N1CSOCC1 DLFWLHAFKJXQFP-UHFFFAOYSA-N 0.000 description 1
- UUIQBSIKJZRPKD-UHFFFAOYSA-N 1,1-dimethyl-2-[5-(methylsulfanylmethyl)-2-morpholin-4-ylphenyl]guanidine Chemical compound CN(C)C(N)=NC1=CC(CSC)=CC=C1N1CCOCC1 UUIQBSIKJZRPKD-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BCQIXIZMDBMYDB-UHFFFAOYSA-N 2-(2-morpholin-4-ylphenyl)guanidine Chemical compound NC(N)=NC1=CC=CC=C1N1CCOCC1 BCQIXIZMDBMYDB-UHFFFAOYSA-N 0.000 description 1
- DSHPEUMNBHBDRW-UHFFFAOYSA-N 2-(3-chloro-2-morpholin-4-ylphenyl)-1,1-dimethylguanidine Chemical compound CN(C)C(N)=NC1=CC=CC(Cl)=C1N1CCOCC1 DSHPEUMNBHBDRW-UHFFFAOYSA-N 0.000 description 1
- AKNMIDRCCYRVMN-UHFFFAOYSA-N 2-(4-chloro-2-morpholin-4-ylphenyl)-1,1-dimethylguanidine Chemical compound CN(C)C(N)=NC1=CC=C(Cl)C=C1N1CCOCC1 AKNMIDRCCYRVMN-UHFFFAOYSA-N 0.000 description 1
- LGTLXSYUSFFCRQ-UHFFFAOYSA-N 2-(5-ethyl-2-morpholin-4-ylphenyl)-1,1-dimethylguanidine Chemical compound CN(C)C(N)=NC1=CC(CC)=CC=C1N1CCOCC1 LGTLXSYUSFFCRQ-UHFFFAOYSA-N 0.000 description 1
- BDBQEPCNYHQKHK-UHFFFAOYSA-N 2-(5-methoxy-2-morpholin-4-ylphenyl)-1,1-dimethylguanidine Chemical compound CN(C)C(N)=NC1=CC(OC)=CC=C1N1CCOCC1 BDBQEPCNYHQKHK-UHFFFAOYSA-N 0.000 description 1
- KOHBEDRJXKOYHL-UHFFFAOYSA-N 2-methoxy-n-methylethanamine Chemical compound CNCCOC KOHBEDRJXKOYHL-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- YQWKOWYZWMCMJV-UHFFFAOYSA-N 2-methyl-n'-(5-methylsulfanyl-2-morpholin-4-ylphenyl)propanimidamide Chemical compound CC(C)C(=N)NC1=CC(SC)=CC=C1N1CCOCC1 YQWKOWYZWMCMJV-UHFFFAOYSA-N 0.000 description 1
- QRJZGVVKGFIGLI-UHFFFAOYSA-N 2-phenylguanidine Chemical compound NC(=N)NC1=CC=CC=C1 QRJZGVVKGFIGLI-UHFFFAOYSA-N 0.000 description 1
- IIDYOEJOFYEQMP-UHFFFAOYSA-N 5-(2-methylpropyl)-2-morpholin-4-ylaniline;hydrochloride Chemical compound Cl.NC1=CC(CC(C)C)=CC=C1N1CCOCC1 IIDYOEJOFYEQMP-UHFFFAOYSA-N 0.000 description 1
- NSVHSRBHIFWVGP-UHFFFAOYSA-N 5-fluoro-2-morpholin-4-ylaniline Chemical compound NC1=CC(F)=CC=C1N1CCOCC1 NSVHSRBHIFWVGP-UHFFFAOYSA-N 0.000 description 1
- FABHEYAZAOCBCH-UHFFFAOYSA-N 5-methyl-2-morpholin-4-ylaniline Chemical compound NC1=CC(C)=CC=C1N1CCOCC1 FABHEYAZAOCBCH-UHFFFAOYSA-N 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical class [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- RIPYGTPGAMWYIX-UHFFFAOYSA-N methoxymethyl thiohypofluorite Chemical compound COCSF RIPYGTPGAMWYIX-UHFFFAOYSA-N 0.000 description 1
- QMPBGXKGFCGWPA-UHFFFAOYSA-N methyl 3-amino-4-morpholin-4-ylbenzoate Chemical compound NC1=CC(C(=O)OC)=CC=C1N1CCOCC1 QMPBGXKGFCGWPA-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GAGYTSOEDMAYIA-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)butanimidamide Chemical compound CCCC(=N)NC1=CC=CC=C1N1CCOCC1 GAGYTSOEDMAYIA-UHFFFAOYSA-N 0.000 description 1
- HFJHZSQLRZVYMR-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)morpholine-4-carboximidamide Chemical compound C1COCCN1C(=N)NC1=CC=CC=C1N1CCOCC1 HFJHZSQLRZVYMR-UHFFFAOYSA-N 0.000 description 1
- BLUUWKVYAFKWFO-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)propanimidamide Chemical compound CCC(=N)NC1=CC=CC=C1N1CCOCC1 BLUUWKVYAFKWFO-UHFFFAOYSA-N 0.000 description 1
- ZKGWYQRILKGVKS-UHFFFAOYSA-N n'-(2-morpholin-4-ylphenyl)pyrrolidine-1-carboximidamide Chemical compound C1CCCN1C(=N)NC1=CC=CC=C1N1CCOCC1 ZKGWYQRILKGVKS-UHFFFAOYSA-N 0.000 description 1
- SXUKWCFCQIRVIL-UHFFFAOYSA-N n'-(2-piperidin-1-ylphenyl)morpholine-4-carboximidamide Chemical compound C1COCCN1C(=N)NC1=CC=CC=C1N1CCCCC1 SXUKWCFCQIRVIL-UHFFFAOYSA-N 0.000 description 1
- JYIZFVNGKKMMCD-UHFFFAOYSA-N n'-(2-piperidin-1-ylphenyl)piperidine-1-carboximidamide Chemical compound C1CCCCN1C(=N)NC1=CC=CC=C1N1CCCCC1 JYIZFVNGKKMMCD-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- GNFWGDKKNWGGJY-UHFFFAOYSA-N propanimidamide Chemical compound CCC(N)=N GNFWGDKKNWGGJY-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
- Soy Sauces And Products Related Thereto (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Description
Šis išradimas skirtas naujų terapinių junginių, naudingų kaip priešdiabetinės medžiagos, būtent hipoglikeminių medžiagų ir farmacinių kompozicijų, į kurias įeina šie junginiai, gavimo būdui.
JAV patente US-077978 siūlomi kondensuotą biciklinį žiedą turintys amidai diabetinės nefropatijos ir diabetinės retinopatijos gydymui. Kanados patente CA-372219-1 aprašomi N-naftoil- ir N-tionaftoilglicino dariniai, o JAV patente US-672015 aprašomi perfluorinti N-meti1-N-naftoilglicino dariniai, kurie yra efektyvūs aldozreduktazės inhibitoriai ir tuūlomi naudokurių formu(I) , yra morfolino, piperidino, pirolidino, tiamorfolino, metilpiperazino, N,N-dimetilamino ir N-(metoksietil)-N-metiiamino grupės;
yra NH^ grupė, kai NR^Rg yra N, N-dimeti.Lamino, N,N-dietilamino, N-butil-N-metilamino, N,N-bis(metoksietil)amino, morfolino, pirolidino arba piperidino grupės;
n hipoglikeminį poveikį. Šie glicino dariniai si ti diabeto ir su juo susijusių ligų gydymui.
Konkrečiau, šis išradimas skirtas junginių, lė (I):
NR1R2
R, / 3
NRCR, □ O ir jų farmaciškai tinkamų druskų, kuriuose
R_, yra vandenilio atomas, metilas, etilas, izobutilas, metoksi grupė, metiltiogrupė, fluoras arba chloras; gavimo būdui.
Išradime siūlomas būdas apima diaminų, kurių formulė (II)
kurioje NR^R^ ir R? turi aukščiau minėtas reikšmes, reakciją su junginiu, kurio formulė (III):
R'-CN (III) kurioje R' turi tas pačias reikšmes, kaip ir R^, jeigu norima gauti junginius, kuriuose R^ ir Rg yra vandenilio atomai (reakcijoje gali būti naudojamas aliuminio chloridas) ir R' yra R^RgN- grupė, jeigu norima gauti junginius, kuriuose R- yra grupė (reakcijoje gali būti naudojamas m-krezolis).
Geriausia reakciją atlikti 90-170 °C temperatūroje ir vykdyti ją tol, kol pilnai sureaguoja.
Specifiniai (I) formulės junginiai yra:
N-(2-morfolinofenil)acetamidinas,
H-(5-metil-2-morfolinofenil)acetamidinas,
N-(2-morfolinofenil)propionamidinas,
N-(2-morfolinofenil)butiramidinas,
N - ( 2-morf olinof enil ) izobutiramidinas ,
N-{5-metiltio-2-morfolinofenil)izobutiramidinas,
N-(5-fluor-2-morfolinofenil)izobutiramidinas,
N-(2-morfolinofenil)valeramidinas,
N-(2-morfolinofenil)pivalamidinas,
2-(2-morfolinofenilguanidinas,
1.1- dimetil-2-(5-metil-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(6-meti1-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(4-chlor-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(3-chlor-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(5-metoksi-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(5-metiltio-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(4-meti1-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(5-etil-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(5-metiltiometil-2-morfolinofenil)guanidinas,
1.1- dimetil-2-(2-morfolinofenil)guanidinas, i-(n-butil)-1-meti1-2-(2-morfolinofenil)guanidinas,
1.1- bis-(2-metoksietil)-2-(2-morfolinofenil)guanidinas,
N-(2-morfolinofenil)morfolin-4-karboksamidinas,
N-(2-morfolinofenil)pirolidin-l-karboksamidinas,
1.1- dimetil-2-(2-morfolinofenil)guanidinas,
1.1- dimetil-2-(2-piperidinofenil)guanidinas,
1.1- dimetil-2-/2-(1-pirolidinil)fenil/guanidinas,
1.1- dimetil-2-(2-tiamorfolinpfenil)guanidinas,
1.1- dimetil-2-(2-dimetilaminofenil)guanidinas,
1.1- dimetil-2- 2-/N-(2-metoksietil)-N-metilamino/fenil guanidinas,
1.1- dimetil-2-/2-(4-metil-l-piperazinil)fenil/guanidinas, N-(2-piperidinofenil)morfolin-4-karboksamidinas, N-(2-piperidinofenil)piperidin-l-karboksamidinas,
1.1- dimetil-2-(5-metoksikarboni1-2-morfolinofenil)guanidina ir jų farmaciškai tinkamos druskos.
(I) formulės junginiai gali egzistuoti druskų su farmaciškai tinkamomis rūgštimis pavidalu. Tokių druskų pavyzdžiais gali būti hidrochloridai, hidrobromidai, hidrojodidai, sulfatai, nitratai, maleatai, acetatai, citratai, fumaratai, tartratai, sukcinatai, benzoatai, pamoatai ir druskos su rūgščiomis amincrūgštimis, tokiomis kaip glutamino rūgštis. (I) formulės junginiai ir jų druskos gali egzistuoti solvatų formoje (pavyzdžiui, hidratai).
Kai kurie (I) formulės junginiai turi vieną arba daugiau asimetrinių anglies atomų ir egzistuoja įvairiose optiškai aktyviose formose. Jeigu (I) formulės junginiai turi vieną chiralinį centrą, tai junginiai egzistuoja dviejose enantiomerinėse formose, ir šis išradimas apima abi šias enantiomerines formas ir jų mišinius, jeigu (I) formulės junginiai turi daugiau negu vieną chiralinį centrą, tai junginiai gali egzistuoti diastereoizomerinėse formose, šis išradimas apima kiekvieną iš šių diastereoizomerinių formų ir jų mišinius.
Šis išradimas apima taip pat ir farmacines kompozicijas, į kurias įeina terapiškai efektyvus (I) formulės junginio kiekis kartu su farmaciškai tinkamu skiedikliu arba nešėju.
Junginius naudojant terapijoje, veiklusis junginys gali būti vartojamas peroraliniu, rektaliniu, parenteriniu arba vietiniu būdu, geriausia peroraliniu būdu. Taigi, pagal šį išradimą, terapinės kompozicijos gali turėti bet kokią žinomą farmacinės kompozicijos, skirtos peroraliniam, rektaliniam, parenteriniam arba vietiniam naudojimui, formą. Farmaciškai tinkami nešėjai, kurie gali būti naudojami tokiose kompozicijose, yra gerai žinomi šioje srityje. Pagal šį išradimą, kompozicijose gali būti 0,1-90 svorio % veikliojo junginio. Pagal šį išradimą, kompozicijos paprastai gaminamos dozuotų vienetų formoje.
Peroraliniam vartojimui skirtos kompozicijos, pagal šį išradimą, naudojamos žinomų vaistinių formų pavidalu, pavyzdžiui, kaip tabletės, kapsulės, sirupai, suspensijos vandenyje arba aliejuje. Vaisto terpė, naudojama minėtose kompozicijose, yra farmakologijoje gerai žinomas indiferentinės sudėtinės vaistų dalys. Tabletės gali būti gaunamos sumaišant veiklųjį junginį su inertiniu skiedikliu, tokiu kaip kalcio fosfatas, esant dezintergruojantiems agentams, pavyzdžiui, kukurūzų krakmolui, ir sutepančioms medžiagoms, pavyzdžiui, magnio stearatui. Mišinys tabletuojamas žinomais būdais, ^agal išradimą, tabletės gali būti pagamintos šios srities specialistams žinomais būdais taip, kad junginio išsiskyrimas būtų ilgalaikis. Jeigu reikia, tokios tabletės gali turėti enterotirpų apvalkalėlį, padengiant jas žinomais būdais, pavyzdžiui, panaudojant celiuliozės acetato ftalatą. Lygiai taip pat tradiciniais būdais gali būti pagaminamos kapsulės, pavyzdžiui, kietos arba minkštos želatinos kapsulės, kuriose yra veiklioji medžiaga su pridėtais užpildais arba be jų, ir, jeigu reikia, gali turėti tirpų žarnyne apvalkalėlį, gaunamą žinomais būdais. Kiekvienoje tabletėje arba kapsulėje tradiciškai gali būti 50-500 mg veikliojo junginio. Kitos kompozicijos, skirtos peroraliniam vartojimui, apima, pavyzdžiui, vandeninius veikliojo junginio tirpalus, vandenines veikliojo junginio suspensijas, į kurias įeina netoksinė suspenduojanti medžiaga, tokia kaip natrio karboksimetilceliuliozė, ir suspensijas, į kurias įeina šio išradimo veiklioji medžiaga tinkamame augaliniame aliejuje, pavyzdžiui, žemės riešutų aliejuje.
Šių junginių panaudojimui gali būti tinkamos kai kurios kompozicijos/ į kurias įeina labai mažų dydžių dalelės, pavyzdžiui, gaunamos skysto malimo būdu.
Pagal šį išradimą, kompozicijose, jeigu norima, veiklusis junginys gali būti naudojamas deriniuose su kitais farmakologiškai suderinamais ingredientais.
Farmacinės kompozicijos, į kurias įeina terapiškai efektyvus (I) formulės junginio kiekis, gali būti naudojamos žmonių hiperglikemijos gydymui. Tokio gydymo atveju (I) formulės junginio kiekis, suvartojamas per dieną, yra 50-3000 mg ribose. Tinkamiausias vartojimo būdas yra per burną.
(I) formulės junginių, kurie duoti tolimesniuose pavyzdžiuose, hipoglikeminis aktyvumas buvo patvirtintas tokiu testu. Žiurkės, sveriančios po 150-200 g, fiksuojamos 18 valandų, tada po oda įleidžiama gliukozės (800 mg /4 ml /kg), o po to per gerklę duodama tiriamųjų junginių (x mg /4 arba 5 ml 2 %·· agaro / kg). Po 2 ir 4 valandų paimama kraujo iš akiduobės, ir gliukozės kiekis plazmoje įvertinamas Bekmano gliukozės analizatoriumi, panaudojant specifinį gliukozės oksidini mo metodą (Kadish A.H., Little R.L. and Struberg J.C., Clin. Chem., 14, 116 (1968)). Po to išskaičiuojamas gliukozės kiekio plazmoje sumažėjimas procentais, lyginant su kontroliniais gyvuliukais, kurie negavo tiriamojo junginio, o gavo tik 2 % agaro nomogenatą. Laikoma, kad junginiai šiame teste pasižymi hipoglikeminiu aktyvumu, jeigu jie sukėlė 15 arba daugiau % gliukozės kiekio plazmoje sumažėjimą, esant bet kokioms x reikšmėms iki 200 tiek po 2-jų, tiek ir po 4-rių valandų. Rezultatai, gauti aukščiau aprašytuose testuose, esant bet kokioms x reikšmėms, vertinant kiekvieno junginio hipergiikeminį ak7 tyvumą, klasifikuoti pagal tokią skalę. Jeigu, esant konkrečiam x, buvo atlikta daugiau negu viena bandymų serija, junginių aktyvumo klasifikacijai imtas vidutinis sumažėjimo procentas .
A - daugiau negu 25 % sumažėjimas po 2 valandų ir po 4 valandų nuo junginio įvedimo.
B - daugiau negu 25 % sumažėjimas po 2 valandų, bet mažesnis negu 25 % sumažėjimas po 4 valandų.
C - sumažėjimas 15-25 % ribose po 2 valandų, bet didesnis negu 25 % - po 4 valandų.
D - sumažėjimas 15-25 % ribose tiek po 2, tiek ir po 4 valandų.
E - sumažėjimas 15-25 % ribose po 2 valandų, bet mažesnis negu 15 % - po 4 valandų.
F - sumažėjimas mažesnis negu 15 % po 2 valandų, bet didesnis negu 15 % - po 4 valandų.
Toliau duodamuose pavyzdžiuose aprašytų junginių aktyvu-
mas | parodytas | 1 lentelėje | • | 1 | lentelė |
Pvz. | X | aktyvumas | Pvz. | X | ' .aktyvumas |
Nr. | Nr. | ||||
X | 200 | A | 10 | 25 | B |
2 | 25 | B | 11 | 36 | B |
3 | 27 | A | 12 | 200 | D |
4 | 37 | E | 13 | 37 | A |
5 | 37 | E | 14 | 36 | A |
6 | 25 | E | 15 | 36 | B |
7 | 25 | B | 16 | 25 | E |
8 | 25 | B | 17 | 35 | E |
9 | 36 | B | 1 18 | 200 | A |
lentelė (tęsinys)
Pvz. Nr. | X | aktyvumas | Pvz. Nr. | X | aktyvumas |
19 | 35 | A | 30 | 36 | B |
20 | 36 | B | 31 | 200 | E |
21 | 36 | A | 32 | 200 | E |
22 | 34 | B | • 33 | 200 | E |
23 | 36 | A | 34 | 35 | B |
24 | 35 | E | 35 | 35 | B |
25 | 34 | D | 36 | 25 | B |
26 | 35 | B | 37 | 25 | B |
27 | 36 | C | 38 | 25 | D |
28 | 37 | B | 39 | 25 | B |
29 | 37 | B |
Šis išradimas iliustruojamas toliau duodamais pavyzdžiais, kurie neriboja jo apimties. Kiekvieno pavyzdžio produktas charakterizuotas elementinės analizės duomenimis.
pavyzdys
4-(2-aminofenil)morfolino (5,34 g), acetonitrilo (4,52 ml) ir bevandenio aliuminio chlorido (12 g) mišinys šildomas 160-170 °C temperatūroje 4 valandas ir gaunamas.N-(2-morfolinofenil)acetamidinas, kuris perkristalinamas iš heksano (lyd. temp.: 140-141 °C).
pavyzdys
4-(2-amino-4-metilfenilJmorfolino (5,75 g), acetonitrilo (3,5 g) ir bevandenio aliuminio chlorido (12 g) mišinys šildomas 160-170 °C temperatūroje penkias valandas ir gaunamas N-(5-metil-2-morfolinofenil)acetamidinas, kuris perkristalinamas iš heksano (lyd. temp.: 121 °c).
pavyzdys
4-(2-aminofenil)morfolino (5,34 g), propionitrilo (4,7 g) ir bevandenio aliuminio chlorido (12 g) mišinys šildomas 160o * *
-170 C temperatūroje sesias valandas ir gaunamas N-(2-morfclinofenil)propionamidinas, kuris perkristalinamas iš heksano (lyd. temp.: 114 °C).
pavyzdys
4-(2-aminofenil)morfolino hidrochlorido (7,5 g) ir n-butironitrilo (20 ml) mišinys šildomas 170 C temperatūroje hermetiškame inde iš nerūdijančio plieno, skirtame aukštiems slėgiams, 60 valandų. n-Butironitrilo perteklius pašalinamas, liekana tirpinama vandenyje, pašarminama 10 % natrio hidroksido tirpalu iki pH 12 ir ekstrahuojama dichlormetanu. Ekstraktas perplaunamas vandeniu, po to druskos tirpalu, džiovinamas ir nugarinamas tirpiklis. Liekana valoma chromatografuojant per kolonėlę su neutraliu aliuminio oksidu. Eliuuojant dichlormetano ir heksano mišiniu (1:1), pašalinta nesureagavusi pradinė medžiaga, o po to, eliuuojant metanolio/dichlormetano mišiniu (1:99), buvo gauta kieta medžiaga, kurią ištirpinus metanolyje (10 ml) ir apdorojus fumaro rūgštimi (0,4 g), gautas N-(2-morfolinofenil)butiramidino monofumaratas, kuris perkristalinamas iš metanolio/eterio mišinio santykiu 1:2 (lyd. temp.: 168-170 °C).
pavyzdys
Į maišomą mišinį, susidedantį iš 4-(2-aminofenil)morfolino (5,34 g) ir n-butironitrilo (6 g) 50-40 °c temperatūroje dalimis pridedama sumalto į miltelius bevandenio aliuminio chlorido (12 g). Po to mišinys šildomas 160-170 °C temperatū10 roję šešias valandas, po to pašarminamas 40 % vandeniniu natrio hidroksido tirpalu. Tirpalas ekstrahuojamas eteriu, ekstraktas perplaunamas vandeniu ir druskos tirpalu ir džiovinamas. Nugarinus tirpiklį, gauta liekana, kuri perkristalinama iš etilacetato/heksano mišinio (1:1). Gautas N-(2-morfolinofenil)butirami dinas (lyd. temp.: 131 °C) paverstas į jo monofumaro druską (lyd. temp.: 173 °C), perkristalinamą iš propan-2-olio.
pavyzdys
4-(2-aminofenil)morfolino hidrochlorido (10 g) ir izobutironitrilo (60 ml) mišinys šildomas 165 °C temperatūroje hermetiškame aukšto slėgio inde iš nerūdijančio plieno 26 valandas ir gaunamas N-(2-morfolinofenil)izobutiramidinas, kuris perkristalinamas iš heksano (lyd. temp.: 140-141 °C).
pavyzdys
4- (2-aminofenil)morfolino (5,34 g), izobutironitrilo (6 g) ir bevandenio aliuminio chlorido (12 g) mišinys šildomas 160-170 °C temperatūroje šešias valandas ir gaunamas N-(2-morfolinofenil)izobutiramidinas, kuris perkristalinamas iš etiiacetato/heksano mišinio santykiu 1:1 (lyd. temp.: 138 C).
pavyzdys
5- t4etiltio-2-morfolinoanilino (1,8 g), izobutironitrilo (1,66 g) ir bevandenio aliuminio chlorido (3,2 g) mišinys šildomas 140 °C temperatūroje dvi valandas ir gaunamas N-(5-metiltio-2-morfolinofenil)izobutiramidinas, kuris perkristalinamas iš heksano (lyd. temp.: 155 °C).
pavyzdys
5-Fluor-2-morfolinoanilino (1,96 g), izobutironitrilo (2 g) ir bevandenio aliuminio chlorido mišinys šildomas 150 °C temperatūroje keturias valandas ir gaunamas N-(5-fluor-2-morfolinofenil)izobutiramidinas (lyd. temp.: 142 °C) , kuris buvo perkristalintas iš heksano ir paverstas į jo fumaro druską (lyd. temp.: 172 °C), kuri perkristalinta iš metanolio/eterio mišinio santykiu 1:1.
pavyzdys
4-(2-aminofenil)morfolino (6,5 g) ir valeronitrilo (35 ml) mišinys buvo šildomas 160-165 °C temperatūroje ir azoto atmosferoje 25 valandas, o po to atšaldomas. Į mišinį pridedama vandeninio natrio hidroksido tirpalo ir pašarmintas mišinys ekstrahuojamas dichlormetanu. Tirpiklis nugarinamas, o liekaha distiliuojama esant 50 mm Hg stulpelio slėgiui, kol iriudistiiiuo .gama : pusė nesureagavusio valeronitrilo. Kieta medžiaga, kuri išsiskyrė atšaldžius, buvo atskirta filtravimo būdu, perplauta heksanu (50 ml) ir perkristalinta iš heksanc. Gaunamas N-(2-morfolinofenil)vaieramidinas (lyd. temp.: 135-136 °C).
pavyzdys
4-(2-aminofenil)morfolino (3,56 g), pivalonitrilo (5 g) ir bevandenio aliuminio chlorido ’(8 g) mišinys kaitinamas 160-170 °C temperatūroje šešias valandas ir gaunamas N-(2-morfolinofenil)pivalamidinas (lyd. temp.: 126 °C), kuris perkristalintas iš heksano ir paverstas į jo monofumaratą (lyd. temp.: 211 °C), perkristalintą iš metanolio.
12-35 pavyzdžiai
Veikiant junginių, kurių formulė (II), hidrochloridus (K gr mų) , junginiais, kurių formulė NC-NE^r^ (L gramų) meta-krezole (M ml) , šildant 90-95 °C temperatūroje N valandų, gaunami junginiai, kurie identifikuoti 2-je lentelėje.
Pastabos 2 lentelei (1) Produktas perkristalintas iš etilacetato (2) Produktas išskirtas monofumarato forma; ši druska perkristalinta iš metanolio.
(3) Produktas perkristalintas iš heksano.
(4) Reakcija atliekama 110 °C temperatūroje.
(5) Produktas išskirtas monofumarato formoje; druska perkristalinama iš metanolio-eterio (1:2) mišinio.
(6) Produktas išskirtas monofumarato formoje; ši druska perkristalinta iš metanolio-eterio (1:1) mišinio.
(7) Reakcija vykdoma 90-95 °C temperatūroje 8 valandas ir po to 115-120 °C temperatūroje - 4 valandas.
(8) Reakcija vykdoma 120-125 °C temperatūroje.
(9) Reakcijos mišinys šildomas 90-95 °C temperatūroje 9 va landas, po to 120 °C temperatūroje 21 valandą.
(10) Iš reakcijos mišinio gauta alyva, kuri išekstrahuota verdančiu heksanu, ir gauta laisva bazė paversta monofumaratu, kuris perkristalinamas iš metanolio-eterio (1:3) mišinio.
(11) Iš reakcijos mišinio gauta alyva, kuri ekstrahuojama heksanu ir gaunama alyvos pavidalo laisva bazė, kuri valoma chromatografuojant per kolonėlę su neutraliu aliuminio oksidu iš eilės naudojant tokius eliuentus: heksaną, dichlormetano-heksano (1:1) mišinį, dichlormetaną ir metanolio-dichlormetano (1:99) mišinį; gaunama bazė, kuri perkristalinama iš metanolio-eterio (2:7) mišinio.
•φ ι-H
O
4j
C
CN (N a
rH
Oi
CN
S, z
N u
II z
C£>
a cn
U
Z r*
CS (0
J3 ra •U cn ra
CU υ
o •U t
Ό
CS
CN
CS i—4 cs «a,
N · > U O, 2
-—s | Χ-Χ. | >—s | >-s. | z—s | m | CM | CM | |||||
r-) | CM | ro | CM | r4 | CM | CM | CM | CM | CM | *-* | — | |
«Μ* | N** | «Μ* | »«✓ |
kO r-H CM | ro CM t—4 | r—i ro CM t | CM <n i | (0 t—4 > dd cn | kO CM CM I | 00 r—4 CM I | o o CM « | cn rH I | 00 co r-4 I | |||
O> | 1 uo | CM | 1 O | CM | 1 O | o | o | 1 uo | 1 | 1 00 | f ro | 1 r^· |
CO | r—f | CM | co | uo | cn | CM | CN | CM | i-4 | cn | Oi | oo |
1-1 | CM | «—4 | CM | i—4 | I—I | CM | CN | CM | 03 | i—4 | <—1 | »—1 |
G) | ||||||||||||
X | 2Ξ | 0) | Φ | r—i | f—f | G) | <U | *T* <—» | -P | G) | X | X |
s | S | U | U | s | S | 1 | w | 2 | ||||
1 | 1 | 1 | 1 | o | ω | uo | 1 | W | ||||
*3* | ro | UO | kO | i | 1 | «31 | CM | |||||
Ν' | X |
u
I
Ν'
O <U CJ CD
Ξ S S S (U 0) (D
S S S <u tu s
CJ
4J 3 ta ta y-i
M
O ε
OJ OJ CJ s s s
0) (D O o s s s
4J CJ
CJ S (CH9)2 OMe (CIU)_0Me H 160-162 (6) (7) m in
co | m | m | o | CN | O | CO | CO | kO | σ» | o | uo | 00 | 1 |
1—4 | UO | r-4 | j—4 | CM | »—4 | ||||||||
m | o | m | uo | o | o | uO | o | m | U0 | o | o | O | O |
CM | co | CM | U0 | uo | CM | CM | CM | *3* | CO | uo | |||
uo | • | M* | uo | CO | |||||||||
00 | u0 | uo | uo | Γ- | CM | <Ti | ·—f | oo | c- | co | |||
—t | cn | U0 | U0 | ro | rO | CM | CM | CM | LT) | uo | kO | CO | |
CM | ’tr | oo | co | CM | ro | oo | oo | kO | kO | —4 | |||
kO | cn | >· | o | r- | r* | kO | kO | UO | UO | co | co | CO | |
i—4 | »—4 | ||||||||||||
CM | ro | ^3* | uo | kO | r* | oo | o | o | i—l | CM | ro | uo | |
*-4 | i—4 | »-4 | r-4 | r-4 | •—4 | r-4 | 1—i | CM | CM | CM | CM | CN | <N |
lentelė (tęsinys)
CM £>
tO ω
cu
OJ 'Ό cn
CM cn «—f cn
-t, uO sn n · > Ui CU 2 co
co
CM
CM
n | 00 | O | CM | O | rn | to | ΟΊ | r- | |
o | co | CO | O | r-d | kO | o | O | »—d | |
CN | CM | —1 | CM | CM | co | r—1 | CN | CM | CM |
1 | 1 | 1 | t | 1 | CO | 1 | 1 | t | 1 |
CN | Γ- | σ> | r—I | CO | r—d | CM | un | 00 · | kO |
O | ΟΟ | oo | O | o | kO | o | o | —d | |
CM | CM | «—d | CM | CM | r—J | CN | CM | CM |
CM
CM
e | e | ω | (U | tu | o | CN | I | ||
CM | 1 | s | -r | 2 | 2 | 2 | 2 | S | \T |
** | |||||||||
a | '— | Cs | |||||||
x*<* | CM | o | 2 | ||||||
o | X | CN | O | ||||||
CM | O | —> | >—· | ||||||
,—. | CN | 1 | |||||||
CN | 1 | 33 | |||||||
33 | U | ||||||||
U | —- | ||||||||
—. | 1 | ||||||||
1 | (U | tu | (U | e | (U | OJ | |||
s | 2 | 2 | 2 | ||||||
1 S4 | |||||||||
O | tu | ||||||||
a | |||||||||
o | 0 | o | •rd | ||||||
i—1 | C | CN | a | ||||||
0 | •H | H | •Ύ1 | 1 | 0 | ||||
0 | c | C | r—f | U | r—d | c | 0 | ||
c | •H | •H | O | CN | CM | 1 | •H | C | |
-H | Ό | Ό | M-t | tu | 1—» | -t 0 | Ό | •H | |
r-4 | •H | •H | 54 | 2 | u | H f—i | Ή | Ή | |
0 | s | G | r—t | O | 2 | s | 4-5 -H | P | 0 |
<w | a | O | e | <D | <U C | e | U-l | ||
M | CL | M | (0 | S H | et | Ud | |||
0 | -H | -H | -H | «*_· | 1 N | Ή | 0 | ||
ε | Oj | a. | 4J | 2 | V (0 | Ch | s |
r- | CM | kO | r-f | kO | CO | co | o | co |
r-d | *—d | rH | »—1 |
o | O | O | O | uO | O | o | o | uo | m |
CM | *4* | CO | CM | m | r—1 | CN | CM | CM |
oo | uo CM | co | —d· | co | UO f- | CM UO | uo K | 00 | |
uo | kO | uo | •=r | CM | CM | r-l | co | UO | uo |
uo | CM | kO | CM | kO | uo | co ro | 00 co | UO | |
Ό | o | O | 03 | <* | —4 | r- | |||
r—I | f—d | r—d |
r*
CM CM co σ>
CM CM
O -H co co
CM CO
CO CO <r cn co co pavyzdys
4-(2-aminofenil)morfolino hidrochlorido (2,1 g) ir N,N-dimetilcianamido (7 ml) mišinys azoto atmosferoje šildomas 165-170 °C temperatūroje 12 valandų. Reakcijos mišinys atšaldomas iki 10 °C, iškritusios nuosėdos nufiltruojamos, perplaunamos eteriu ir sumaišomos su 40 %-niu vandeniniu natrio hidroksido tirpalu. Gautas mišinys ekstrahuojamas dichlormetanu, ekstraktas perplaunamas druskos tirpalu ir džiovinamas. Nugarinus tirpiklį, gaunama liekana, kuri perkristalinama iš heksano. Gaunamas 1,2-dimetil-2-(2-morfolinofenil)guanidinas (lyd. temp.: 144-145 °C.
pavyzdys
4- (2-amino-4-metoksikarbonilfenil)morfolino (2,7 g), N,N-dimetilcianamido (1 g) ir m-krezolio mišinys šildomas 90-95 °C temperatūroje 10 valandų. Tada pridedama ledo ir reakcijos mišinys parūgštinamas iki pH 3, pridedant 2N chloro vandenilio rūgšties, ir gautas mišinys ekstrahuojamas eteriu. Vandeninis sluoksnis atšaldomas, pašarminamas iki pH 8, pridedant kieto natrio bikarbonato, o tada ekstrahuojamas dichlormetanu. Ekstraktas džiovinamas, tirpiklis nugarinamas ir gauta alyvos pavidalo liekana valoma chromatografuojant per kolonėlę su neutraliu aliuminio oksidu. Eliuuojant metanolio/dichlormetano (1:99) mišiniu, gaunamas 1,l-dimetil-2-(5-metoksikarbonil-2-morfolinpfenil)guanidinas (lyd. temp.: 152-154 °C).
pavyzdys
5- Izobutil-2-morfolinoanilino hidrochlorido (4,1 g), N,N-dimetilcianamido (1,77 g) ir m-krezolio (15 ml) mišinys šildomas 90-95 °C temperatūroje šešias valandas ir gaunama liekana, kuri ek stahuojama karštu heksanu, spalva pašalinama medžio anglimi ir va16 loma chromatografuojant per kolonėlę su aliuminio oksidu. Eliu avimui naudojamas metanolio/dichlormetano (2:98) mišinys. Gautas produktas . kristalinamas iš etilacetato/heksano (1:3) mi šinio. Pradinės nuosėdos nufiltruojamos, filtratas išgarinamas ir iš etilacetato/heksano (1:3) mišinio gaunamas 1,2-dimetil-2-(5-izobutil-2-morfolinofenil)guanidinas .
pavyzdys
2-Morfolinoariilino hidrochlorido (19,2 g), m-krezolic (80 ml) ir dimetiicianamido (9,45 g) mišinys šildomas 100 °C temperatūroje penkias valandas, atšaldomas ir supilamas į 40 % vandeninio natrio hidroksido (300 nl) ir ledo (300 g) mišinį. Pridedama vandens (300 ml) ir gauta kieta medžiaga nufiltruojama, perplaunama vandeniu ir tirpinama dichlormetane. Tirpalas džiovinamas, tirpiklis nugarinamas ir gaunama liekana, kuri perkristalinama iš heksano. Gaunamas i,l-dimetil-2-(2-morfolinofenil)guanidinas (lyd. temp.: 142-143 °C).
pavyzdys
Į maišomą N-etil-N-(2-metoksietil)amino (10,3 g) tirpalą bevandeniame benzole (80 ml), atšaldytą iki 5 cC ledo vonioje,, per 10 minučių pridedamas bromciano (5,3 g) tirpalas bevandeniame benzole (20 ml) ir reakcijos mišiniui leidžiama sušilti iki kambario temperatūros. Po to mišinys maišomas per naktį. Tada esant sumažintam slėgiui nugarinamas tirpiklis, o liekana keletą kartų ekstrahuojama bevandeniu eteriu (4x25 ml). Organiniai ekstraktai džiovinami natrio sulfatu, filtruojama, tirpiklis nugarinamas ir gaunamas N-etil-N-(2-metoksietil)cian amidas, kuris yra gelsvos spalvos alyvos pavidalo produktas (6,3 g).
N-(2-aminofenil)morfolino hidrochlorido (2 g), N-etil-N-(2-metoksietil)cianamido (2,5 g) ir m-krezolio (15 ml) mišinys sūdomas 90-95 C temperatūroje 8 valandas. Tada pridedama dar N-etil-N-(2-metoksietil)cianamido (2,5 g) ir šildoma dar 20 valandų. Nugarinus tirpiklį, gaunama gelsva alyvos pavidalo medžiaga, kuri gryninama chromatografuojant per kolonėlę su neutraliu aliuminio oksidu (80 g). Eliuuojama iš pradžių dichlormetanu, po to 1 % metanolio tirpalu dichlormetane ir gaunama bespalvė alyvos pavidalo medžiaga (i g), kuri veikiama fumaro rūgštimi (0,38 g) metanolyje (10 ml) ir gaunamas bespalvės kietos medžiagos pavidalo N-etil-N-(2-metoksietil)-N-/2-(4-morfolino)fenil/guanidino .monofumaratas (0,8 g), kuris perkristalinamas iš metanolio/eterio (1:2) mišinio (lyd. temp.: 170-171 °C).
Claims (1)
1. Junginio, kurio formulė (I):
(I) kurioje NR1^2 rnor^°ūno' piperidino, pirolidino, tiamorfolino, metilpiperazinilo, N,N-dimetilamino arba N-(metoksietil)-N-metilamino liekanos;
R^ yra alkilo grupė, turinti 1-4 anglies atomus, kai R. ir Rg yra vandenilis, arba
R^ yra NH^ grupė, kai NR^Rg yra N,N-dimetilamino, N,N-dietilamino, N-butii-N-metilamino, N,N-bis(metoksietil)amino, morfolino, pirolidinilo arba piperidino liekanos;
R- yra vandenilio atomas, metilas, etilas, izobutilas, metoksigrupė, metiltiogrupė, metiltiometilas, fluoras arba chloras ;
ir jo farmaciškai tinkamų druskų gavimo būdas, besiski r i a n r i s tuo, kad junginys, kurio formulė (II):
R
NH (II) kurioje NR^R^ ir R_ turi aukščiau nurodytas reikšmes, šildomas su junginiu, kurio formulė:
R'CN, kurioje R' yra R- grupė, kai R^ ir Rg yra vandenilis, arba R' yra NR-Rg grupė, kai R^ yra NH2 grupė,
90-170 GC temperatūrų intervale tokį laiką, kokio reikia, kad pilnai įvyktų reakcija, esant arba nesant bevandenio aliuminio chlorido, kai R' yra R^; arba esant arba nesant m-krezclio, kai
R' yra NR_Rg
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898903592A GB8903592D0 (en) | 1989-02-16 | 1989-02-16 | Therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
LTIP1647A LTIP1647A (en) | 1995-08-25 |
LT3960B true LT3960B (en) | 1996-05-27 |
Family
ID=10651840
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTIP1647A LT3960B (en) | 1989-02-16 | 1993-12-21 | Process for preparing hypoglycemic compounds |
LTIP1646A LT3958B (en) | 1989-02-16 | 1993-12-21 | Process for preparing hypoglycemic guanidine derivatives |
LTIP1648A LT3961B (en) | 1989-02-16 | 1993-12-21 | Hypoglycemic compounds, process for preparing thereof and pharmaceutical compositions containing them |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTIP1646A LT3958B (en) | 1989-02-16 | 1993-12-21 | Process for preparing hypoglycemic guanidine derivatives |
LTIP1648A LT3961B (en) | 1989-02-16 | 1993-12-21 | Hypoglycemic compounds, process for preparing thereof and pharmaceutical compositions containing them |
Country Status (26)
Country | Link |
---|---|
US (2) | US5223498A (lt) |
EP (1) | EP0385038B1 (lt) |
JP (1) | JP2545475B2 (lt) |
AT (1) | ATE90074T1 (lt) |
BG (1) | BG60557B1 (lt) |
CS (1) | CS277609B6 (lt) |
DD (1) | DD294023A5 (lt) |
DE (1) | DE68906880T2 (lt) |
DK (1) | DK640889A (lt) |
ES (1) | ES2055115T3 (lt) |
FI (1) | FI95565C (lt) |
GB (1) | GB8903592D0 (lt) |
GE (1) | GEP19981040B (lt) |
HU (1) | HU211571A9 (lt) |
IL (1) | IL92963A (lt) |
LT (3) | LT3960B (lt) |
LV (1) | LV10619B (lt) |
MY (1) | MY105052A (lt) |
NO (1) | NO177993C (lt) |
PL (2) | PL162960B1 (lt) |
PT (1) | PT92770B (lt) |
RO (2) | RO107945B1 (lt) |
RU (3) | RU1826969C (lt) |
UA (2) | UA27713C2 (lt) |
YU (1) | YU48164B (lt) |
ZA (1) | ZA899941B (lt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273712B1 (en) * | 1986-12-27 | 1990-12-12 | Konica Corporation | Light-sensitive silver halide photographic material |
IN172842B (lt) * | 1990-05-17 | 1993-12-11 | Boots Pharmaceuticals Limited | |
GB9418912D0 (en) * | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
WO1996017612A1 (en) * | 1994-12-08 | 1996-06-13 | Knoll Aktiengesellschaft | Use of substituted phenylamidine and phenylguanidine compounds for the treatment of cerebral and cardiac ischaemia, convulsion and sickle cell anaemia |
TW397812B (en) * | 1995-02-11 | 2000-07-11 | Astra Ab | Bicyclic isothiourea derivatives useful in therapy |
WO1997046515A1 (fr) * | 1996-06-04 | 1997-12-11 | Chugai Seiyaku Kabushiki Kaisha | Benzenes substitues ne presentant pas d'effets inhibiteurs |
US6756389B2 (en) * | 1996-08-09 | 2004-06-29 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
US6187203B1 (en) * | 1998-12-01 | 2001-02-13 | Academia Sinica | Sample purification apparatus and method |
AU2230501A (en) * | 1999-12-28 | 2001-07-09 | Nissan Chemical Industries Ltd. | Heterocyclic imino compounds and fungicides and insecticides for agricultural and horticultural use |
CN1395467A (zh) * | 2000-09-07 | 2003-02-05 | 美国拜尔公司 | 用作孕酮受体结合剂的环和非环脒以及包含它们的药物组合物 |
PE20070182A1 (es) * | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US77978A (en) | 1868-05-19 | Improvement in low-water indicators | ||
US672015A (en) | 1900-10-05 | 1901-04-16 | Alfred Schlatter | Automatic switch for groups of transformers. |
CA372219A (en) | 1938-03-01 | Kienzle Fritz | Perforating device |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD81857A (lt) * | ||||
GB861527A (en) * | 1958-05-16 | 1961-02-22 | Ici Ltd | New salts of penicillins |
US3622596A (en) * | 1960-10-14 | 1971-11-23 | A Wander Sa Dr | Carbanilide compounds |
CH459172A (de) * | 1961-09-11 | 1968-07-15 | Wander Ag Dr A | Verfahren zur Herstellung mehrbasischer Verbindungen |
US3867448A (en) * | 1962-03-08 | 1975-02-18 | Ciba Geigy Ag | Trifluoromethylphenyl-formamadines and acetamidines |
NL299929A (lt) * | 1962-10-30 | |||
US3479437A (en) * | 1963-08-26 | 1969-11-18 | Stauffer Chemical Co | Guanidine complexes as fungicides |
US3320229A (en) * | 1963-08-26 | 1967-05-16 | Stauffer Chemical Co | Complexes of guanidines with completely halogenated acetones |
US3636219A (en) * | 1964-03-02 | 1972-01-18 | Du Pont | Anticholinergic compositions containing certain thiazolines or imidazolines |
US3399211A (en) * | 1964-03-10 | 1968-08-27 | Merck & Co Inc | Production of 2-aryl-4(5)-nitroimidazoles |
US3479401A (en) * | 1966-06-28 | 1969-11-18 | Merck & Co Inc | Guanidinoaryl and guanidinomethylaryl compounds |
DE1670274A1 (de) * | 1966-10-31 | 1970-07-16 | Boehringer Sohn Ingelheim | Neues Verfahren zur Herstellung von 2-Arylamino-1,3-diazacycloalkenen-(2) |
IL30281A (en) * | 1967-07-11 | 1971-12-29 | Chinoin Gyogyszer Es Vegyeszet | Amidine history and process for their preparation |
US3925471A (en) * | 1970-06-13 | 1975-12-09 | Bayer Ag | Aminophenylamidines their production and their medicinal use |
US3925470A (en) * | 1970-06-13 | 1975-12-09 | Bayer Ag | Aminophenylamidines, their production and their medicinal use |
US3903302A (en) * | 1970-06-13 | 1975-09-02 | Bayer Ag | Aminophenylamidines as anthelmintic agents |
US3919315A (en) * | 1970-06-13 | 1975-11-11 | Bayer Ag | New aminophenylamidines, their production and their medicinal use |
US3996247A (en) * | 1970-06-13 | 1976-12-07 | Bayer Aktiengesellschaft | Substituted 4-aminophenylamidines |
US3923888A (en) * | 1970-06-13 | 1975-12-02 | Bayer Ag | Aminophenylamidines, their production and their medicinal use |
US4013676A (en) * | 1970-06-13 | 1977-03-22 | Bayer Aktiengesellschaft | Aminophenylamidines, their production and their pharmaceutical use |
US3911010A (en) * | 1970-06-13 | 1975-10-07 | Bayer Ag | Aminophenylamidines, their production and their pharmaceutical use |
DE2029297A1 (de) * | 1970-06-13 | 1971-12-30 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Neue Aminophenyl-cycloamidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE2029299C3 (de) * | 1970-06-13 | 1980-08-21 | Bayer Ag, 5090 Leverkusen | Neue Aminophenylamidine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US3911013A (en) * | 1970-06-13 | 1975-10-07 | Bayer Ag | New aminophenylamidines, their production and their medicinal use |
US4018814A (en) * | 1970-06-13 | 1977-04-19 | Bayer Aktiengesellschaft | Aromatic amides and carbomates of phenylamidines |
US3911014A (en) * | 1970-06-13 | 1975-10-07 | Bayer Ag | Aminophenylamidines, their production and their medicinal use |
DE2029298C3 (de) * | 1970-06-13 | 1980-04-17 | Bayer Ag, 5090 Leverkusen | Aminophenylamidine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
FR2098352A7 (en) * | 1970-07-13 | 1972-03-10 | Fahlberg List Veb | Hydroxyguanidines - with selective herbicidal activity |
GB1311913A (en) * | 1970-09-05 | 1973-03-28 | Fahlberg List Veb | Herbicidal hydroxyguanidines |
US3897474A (en) * | 1972-10-12 | 1975-07-29 | Ciba Geigy Corp | Thiol and dithiol carbamate acid ester derivatives of phenyl formamidine |
US3965176A (en) * | 1973-06-20 | 1976-06-22 | Schering Corporation | Novel substituted amidines |
IL44905A (en) * | 1973-06-25 | 1977-03-31 | Ciba Geigy Ag | N-alkyl-n-(n-alkylformimidoyl)-n'-phenylformamidine derivatives their preparation and use in pest control |
SE7411169L (sv) * | 1974-09-04 | 1976-03-05 | Wander Ag Dr A | Forfarande for framstellning av nya organiska foreningar |
JPS51118832A (en) * | 1975-04-09 | 1976-10-19 | Sumitomo Chem Co Ltd | A non-medical antibacterial, 3-pyridyl substituted guanidine |
US4211867A (en) * | 1976-03-19 | 1980-07-08 | Mcneil Laboratories, Incorporated | Nitrogen heterocyclic carboximidamide compounds |
DE2626128A1 (de) * | 1976-06-11 | 1977-12-22 | Beiersdorf Ag | N-substituierte benzimidazolin-2-one und verfahren zu deren herstellung |
US4414211A (en) * | 1978-09-18 | 1983-11-08 | Mcneilab, Inc. | Heterocyclic derivatives of guanidine |
US4182865A (en) * | 1978-09-18 | 1980-01-08 | Mcneil Laboratories, Inc. | Diaza-cyclic derivatives of guanidine |
DE2848786C3 (de) * | 1978-11-10 | 1981-05-21 | Ibm Deutschland Gmbh, 7000 Stuttgart | Schaltungsanordnung für die Synchronisierung der Auftrittszeitpunkte von Druckhammeraufschlag mit dem Eintreffen der Drucktype an der Druckstelle |
AU5263779A (en) * | 1978-11-29 | 1980-05-29 | Beecham Group Limited | Derivatives of thiazolidin-2-ylidene and oxazolidin-2-ylidene with hypoglycaemic acitivity |
US4247705A (en) * | 1979-02-06 | 1981-01-27 | A. H. Robins Company, Inc. | 4-Substituted 2-iminoimidazolidine compounds |
CA1138451A (en) * | 1979-04-03 | 1982-12-28 | Ikuo Ueda | 2-imidazoline derivatives, process for the preparation thereof and the pharmaceutical composition of the same |
ZA802161B (en) * | 1979-04-11 | 1981-04-29 | Ciba Geigy Ag | Guanidines,processes for producing them,and pharmaceutical preparations containing sucn compounds |
IN150250B (lt) * | 1979-04-16 | 1982-08-28 | Ciba Geigy India Ltd | |
EP0018134B1 (en) * | 1979-04-21 | 1984-03-14 | Beecham Group Plc | Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
US4342764A (en) * | 1979-05-29 | 1982-08-03 | Ciba-Geigy Corporation | Guanidine compounds, pharmaceutical compositions and use |
JPS55160764A (en) * | 1979-05-29 | 1980-12-13 | Ciba Geigy Ag | Guanidine* its manufacture and pharmaceutic medicine containing same |
DD144919A1 (de) * | 1979-07-20 | 1980-11-12 | Rainer Beckert | Verfahren zur herstellung von 2,5-diaryl-3,4-diarylimino-1,2,5-thiadiazolidin-s-oxiden |
JPS5618969A (en) * | 1979-07-24 | 1981-02-23 | Toyama Chem Co Ltd | Novel 1-(4-aminobenzyl)-2,3-dioxopiperazine derivative, its acid addition salt, and their preparation |
US4340609A (en) * | 1980-01-02 | 1982-07-20 | William H. Rorer, Inc. | Amidinourea derivative veterinary compositions for suppression of parasitemia |
US4287201A (en) * | 1980-03-03 | 1981-09-01 | Merck & Co., Inc. | Anovulatory method and chicken feed compositions |
US4281004A (en) * | 1980-03-31 | 1981-07-28 | Pfizer Inc. | Phenylguanidine therapeutic agents |
DE3168754D1 (en) * | 1980-07-09 | 1985-03-21 | Beecham Group Plc | Clonidine derivatives useful in the treatment of diarrhoea |
US4348406A (en) * | 1980-10-20 | 1982-09-07 | Schering Corporation | Novel guanidine derivatives |
US4735959A (en) * | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
DE3225188A1 (de) * | 1982-07-06 | 1984-01-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue phenylessigsaeurederivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
DE3100575A1 (de) * | 1981-01-10 | 1982-09-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue benzoesaeuren, ihre herstellung und ihre verwendung als arzneimittel" |
EP0070084A3 (en) * | 1981-04-24 | 1983-02-16 | Beecham Group Plc | Imidazoline derivatives |
US4461904A (en) * | 1981-11-20 | 1984-07-24 | Alcon Laboratories, Inc. | 2-(Trisubstituted phenylimino)-imidazolines |
DE3375783D1 (en) * | 1982-07-06 | 1988-04-07 | Thomae Gmbh Dr K | Phenyl-acetic-acid derivatives, their preparation and pharmaceutical compostions containing them |
US4533739A (en) * | 1982-10-12 | 1985-08-06 | G. D. Searle & Co. | 2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity |
DD216021A5 (de) * | 1983-01-13 | 1984-11-28 | Rhone Poulenc Sante | Verfahren zur herstellung eines neuen pyrrolderivates |
FR2539417A1 (fr) * | 1983-01-13 | 1984-07-20 | Rhone Poulenc Sante | Nouveaux pyrrolo-1, 2 heterocycles, leur preparation et les medicaments qui les contiennent |
SU1114674A1 (ru) * | 1983-02-08 | 1984-09-23 | Предприятие П/Я Р-6913 | Способ получени гидрохлоридов производных @ , @ -дифенил бензамидина |
GB8304593D0 (en) * | 1983-02-18 | 1983-03-23 | Beecham Group Plc | Amidines |
US4735942A (en) * | 1984-01-09 | 1988-04-05 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]-methyl]-1H-imidazoles and 1H-1,2,4-triazoles having antimicrobial properties |
US4861879A (en) * | 1983-02-28 | 1989-08-29 | Janssen Pharmaceutica N.V. | [[4-[4-Phenyl-1-piperazinyl)phenoxymethyl]-1-3-dioxolan-2-yl]-methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
FR2549049B1 (fr) * | 1983-07-13 | 1986-06-20 | Chauvin Blache Lab | Nouvelles amidines, leur procede de preparation et leur application therapeutique |
US4701447A (en) * | 1983-09-23 | 1987-10-20 | Schering Corporation | N-((2-nitro)phenyl)-N' (organic acid) guanidine anthelmintics |
US4723029A (en) * | 1983-09-23 | 1988-02-02 | Schering Corporation | Organic acid-substituted guanidine anthelmintics |
JPS60100559A (ja) * | 1983-11-05 | 1985-06-04 | Morishita Seiyaku Kk | 2−アニリノ−1,6−ジヒドロ−6−オキソ−5−ピリミジンカルボン酸誘導体,その製法及び該化合物を含有する抗アレルギ−剤 |
US4579951A (en) * | 1984-03-19 | 1986-04-01 | G. D. Searle & Co. | Substituted (azacycloalk-2-yl)iminophenols and esters thereof |
US4560690A (en) * | 1984-04-30 | 1985-12-24 | Pfizer Inc. | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents |
EP0164204A1 (en) * | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
HU192986B (en) * | 1984-05-23 | 1987-08-28 | Egyt Gyogyszervegyeszeti Gyar | Process for production of imidasodiline derivatives |
US4656270A (en) * | 1985-03-15 | 1987-04-07 | Mcneilab, Inc. | Process for producing guanidines such as linogliride |
US4693850A (en) * | 1985-03-15 | 1987-09-15 | Mcneilab, Inc. | Methane sulfonic acid derivatives |
DE3518917A1 (de) * | 1985-05-25 | 1986-11-27 | Bayer Ag, 5090 Leverkusen | Substituierte benzochinolizine, verfahren zur herstellung und ihre verwendung in arzneimitteln |
DE3529692A1 (de) * | 1985-08-20 | 1987-02-26 | Bayer Ag | Verwendung von lactamamiden als leistungsfoerderer bei tieren |
CA1292472C (en) * | 1985-12-03 | 1991-11-26 | Alfonsus Guilielmus Knaeps | Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles |
ATE135699T1 (de) * | 1986-01-13 | 1996-04-15 | American Cyanamid Co | 4,5,6-substituierte 2-pyrimidinamine |
GB8602025D0 (en) | 1986-01-28 | 1986-03-05 | Reid M | Orthopaedic trolley |
-
1989
- 1989-02-16 GB GB898903592A patent/GB8903592D0/en active Pending
- 1989-12-13 FI FI895956A patent/FI95565C/fi not_active IP Right Cessation
- 1989-12-14 NO NO895023A patent/NO177993C/no not_active IP Right Cessation
- 1989-12-18 DK DK640889A patent/DK640889A/da not_active Application Discontinuation
- 1989-12-19 MY MYPI89001812A patent/MY105052A/en unknown
- 1989-12-27 CS CS897433A patent/CS277609B6/cs not_active IP Right Cessation
- 1989-12-28 YU YU248589A patent/YU48164B/sh unknown
- 1989-12-28 BG BG90783A patent/BG60557B1/bg unknown
- 1989-12-28 EP EP89313636A patent/EP0385038B1/en not_active Expired - Lifetime
- 1989-12-28 ES ES89313636T patent/ES2055115T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE8989313636T patent/DE68906880T2/de not_active Expired - Fee Related
- 1989-12-28 AT AT89313636T patent/ATE90074T1/de not_active IP Right Cessation
- 1989-12-28 US US07/458,237 patent/US5223498A/en not_active Expired - Lifetime
- 1989-12-28 ZA ZA899941A patent/ZA899941B/xx unknown
- 1989-12-29 RU SU894742813A patent/RU1826969C/ru active
- 1989-12-29 PL PL28307489A patent/PL162960B1/pl unknown
- 1989-12-29 PL PL89295913A patent/PL161961B1/pl unknown
- 1989-12-29 JP JP1345135A patent/JP2545475B2/ja not_active Expired - Fee Related
- 1989-12-29 UA UA5011043A patent/UA27713C2/uk unknown
- 1989-12-29 PT PT92770A patent/PT92770B/pt not_active IP Right Cessation
- 1989-12-29 UA UA4742813A patent/UA19156A/uk unknown
- 1989-12-29 DD DD89336816A patent/DD294023A5/de unknown
- 1989-12-30 RO RO147103A patent/RO107945B1/ro unknown
- 1989-12-30 RO RO143555A patent/RO105807B1/ro unknown
-
1990
- 1990-01-03 IL IL9296390A patent/IL92963A/en not_active IP Right Cessation
- 1990-12-03 RU SU904831862A patent/RU1797610C/ru active
-
1992
- 1992-02-27 RU SU925011043A patent/RU2052452C1/ru active
-
1993
- 1993-01-27 US US08/009,807 patent/US5373008A/en not_active Expired - Fee Related
- 1993-06-30 LV LVP-93-815A patent/LV10619B/en unknown
- 1993-12-21 LT LTIP1647A patent/LT3960B/lt not_active IP Right Cessation
- 1993-12-21 LT LTIP1646A patent/LT3958B/lt not_active IP Right Cessation
- 1993-12-21 LT LTIP1648A patent/LT3961B/lt not_active IP Right Cessation
-
1994
- 1994-10-06 GE GEAP19942233A patent/GEP19981040B/en unknown
-
1995
- 1995-06-30 HU HU95P/P00688P patent/HU211571A9/hu unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US77978A (en) | 1868-05-19 | Improvement in low-water indicators | ||
CA372219A (en) | 1938-03-01 | Kienzle Fritz | Perforating device | |
US672015A (en) | 1900-10-05 | 1901-04-16 | Alfred Schlatter | Automatic switch for groups of transformers. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7416365B2 (ja) | アポトーシス誘発剤 | |
DK171990B1 (da) | 1-Heteroaryl-4-((2,5-pyrrolidindion-1-yl)-alkyl)piperazin-derivater, fremgangsmåder til deres fremstilling samt farmaceutiske midler omfattende disse derivater | |
FI88289C (fi) | Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara fenoxiaettiksyraderivat | |
RU2522578C2 (ru) | Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения | |
LT3960B (en) | Process for preparing hypoglycemic compounds | |
CA1070691A (en) | Guanidine derivatives | |
JP2010536761A (ja) | ネクロトーシスのヘテロ環式抑制剤 | |
WO1998008848A1 (fr) | Derives d'imidazoquinazoline | |
US5872119A (en) | 2-Naphthamide derivatives and their therapeutic applications | |
JP2023524361A (ja) | Tyk2活性を阻害する複素環式化合物 | |
KR20130000402A (ko) | 퓨린 화합물 | |
BG62350B2 (bg) | N-заместени производни на 3-азабицикло/3.2.0/хептан като невролептици и други | |
KR100545474B1 (ko) | 페닐아미노알킬카르복실산 유도체 및 그것을 함유하는의약조성물 | |
RU2323220C2 (ru) | ПРОИЗВОДНЫЕ 2-ЗАМЕЩЕННЫХ ФЕНИЛ-5, 7-ДИГИДРОКАРБИЛ-3, 7-ДИГИДРОПИРРОЛО [2, 3-d] ПИРИМИДИН-4-ОНОВ, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
NZ229144A (en) | Substituted pyrimidinedione derivatives and pharmaceutical compositions, and 1-(1-piperazinyl) isoquinoline as an intermediate reagent | |
KR100259742B1 (ko) | 메토트렉세이트 유도체 | |
JPH07508012A (ja) | 神経弛緩薬等としてのn−置換された3−アザビシクロ[3.2.0]ヘプタン誘導体 | |
US4540696A (en) | 1-Piperazinyl 4-phenylquinazoline compounds having antidepressant properties and drugs containing same | |
CZ325196A3 (en) | Derivatives of hydroximic acid, pharmaceutical compositions containing thereof, process of their preparation and intermediates used in the preparation process | |
JP2012505166A (ja) | 1‐ブチル‐2‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用 | |
SK47598A3 (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the novel compounds | |
RU2114839C1 (ru) | 2,3,4,5-тетрагидро-1н-3-бензазепины, фармацевтическая композиция, способ лечения и способы получения | |
JPH1017555A (ja) | 6−アミノ−5−メチルウラシル誘導体 | |
KR20010072408A (ko) | N-치환 아자비시클로헵탄 유도체, 그의 제조 및 용도 | |
KR100226328B1 (ko) | 4-(4-또는6-(트리플루오로메틸-2-피리디닐))-1-피페라지닐알킬치환된락탐 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM9A | Lapsed patents |
Effective date: 20021221 |